{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T10:23:54Z","timestamp":1770459834935,"version":"3.49.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.critrevonc.2021.103278","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T23:15:40Z","timestamp":1614986140000},"page":"103278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma: A systematic review and meta-analysis of randomized trials"],"prefix":"10.1016","volume":"160","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6925-8603","authenticated-orcid":false,"given":"Chia Ching","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1995-2170","authenticated-orcid":false,"given":"Yu Yang","family":"Soon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balamurugan","family":"Vellayappan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2366-0848","authenticated-orcid":false,"given":"Cheng Nang","family":"Leong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wee Yao","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1363-446X","authenticated-orcid":false,"given":"Jeremy C.S.","family":"Tey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.critrevonc.2021.103278_bib0005","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1148\/radiol.2412051020","article-title":"Pleural mesothelioma: sensitivity and incidence of needle track seeding after image-guided biopsy versus surgical biopsy","volume":"241","author":"Agarwal","year":"2006","journal-title":"Radiology"},{"key":"10.1016\/j.critrevonc.2021.103278_bib0010","first-page":"45","article-title":"SYSTEMS-2: a randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma","volume":"8","author":"Ashton","year":"2018","journal-title":"Clin. Transl. Radiat. Oncol."},{"issue":"Suppl 5","key":"10.1016\/j.critrevonc.2021.103278_bib0015","doi-asserted-by":"crossref","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103278_bib0020","doi-asserted-by":"crossref","first-page":"e010589","DOI":"10.1136\/bmjopen-2015-010589","article-title":"Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention","volume":"6","author":"Bayman","year":"2016","journal-title":"BMJ Open"},{"issue":"14","key":"10.1016\/j.critrevonc.2021.103278_bib0025","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.18.01678","article-title":"Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma: an open-label, multicenter, phase III randomized trial","volume":"37","author":"Bayman","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"3 Suppl","key":"10.1016\/j.critrevonc.2021.103278_bib0030","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ijrobp.2009.09.040","article-title":"Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues","volume":"76","author":"Bentzen","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2021.103278_bib0035","first-page":"38","article-title":"Prophylactic procedure tract radiotherapy for malignant pleural mesothelioma: a systematic review and meta-analysis","volume":"13","author":"Bergamin","year":"2018","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103278_bib0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lungcan.2017.01.019","article-title":"A randomized controlled trial comparing indwelling pleural catheters with talc pleurodesis (NVALT-14)","volume":"108","author":"Boshuizen","year":"2017","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103278_bib0045","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1378\/chest.108.3.754","article-title":"Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy","volume":"108","author":"Boutin","year":"1995","journal-title":"Chest"},{"issue":"Suppl 2","key":"10.1016\/j.critrevonc.2021.103278_bib0050","first-page":"ii1","article-title":"BTS statement on malignant mesothelioma in the UK, 2007","volume":"62","author":"British Thoracic Society Standards of Care","year":"2007","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103278_bib0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.bjc.6601957","article-title":"A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma","volume":"91","author":"Bydder","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103278_bib0060","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0277-5379(89)90266-6","article-title":"Radiation sensitivity of human lung cancer cell lines","volume":"25","author":"Carmichael","year":"1989","journal-title":"Eur. J. Cancer Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103278_bib0065","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0761-8425(04)71235-8","article-title":"[Malignant pleural mesothelioma: radiotherapy for the prevention of seeding nodules]","volume":"21","author":"Cellerin","year":"2004","journal-title":"Rev. Mal. Respir."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103278_bib0070","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/thx.2007.081430","article-title":"Population based epidemiology and prognosis of mesothelioma in Leeds, UK","volume":"63","author":"Chapman","year":"2008","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103278_bib0075","doi-asserted-by":"crossref","first-page":"e006673","DOI":"10.1136\/bmjopen-2014-006673","article-title":"Protocol for the surgical and large bore procedures in malignant pleural mesothelioma and radiotherapy trial (SMART Trial): an RCT evaluating whether prophylactic radiotherapy reduces the incidence of procedure tract metastases","volume":"5","author":"Clive","year":"2015","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.critrevonc.2021.103278_bib0080","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(16)30095-X","article-title":"Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial","volume":"17","author":"Clive","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103278_bib0085","unstructured":"COVIDENCE. 2021 Available from www.covidence.org]."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103278_bib0090","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the radiation therapy oncology group (RTOG) and the european organization for research and treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103278_bib0095","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0167-8140(03)00229-9","article-title":"Treatment of intervention sites of malignant pleural mesothelioma with radiotherapy: a Dutch-Belgian survey","volume":"68","author":"De Ruysscher","year":"2003","journal-title":"Radiother. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2021.103278_bib0100","first-page":"825","article-title":"NCCN guidelines insights: malignant pleural mesothelioma, version 3.2016","volume":"14","author":"Ettinger","year":"2016","journal-title":"J. Compr. Canc. Netw."},{"issue":"7","key":"10.1016\/j.critrevonc.2021.103278_bib0105","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1164\/rccm.201807-1415ST","article-title":"Management of malignant pleural effusions. An official ATS\/STS\/STR clinical practice guideline","volume":"198","author":"Feller-Kopman","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"7650","key":"10.1016\/j.critrevonc.2021.103278_bib0110","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"7651","key":"10.1016\/j.critrevonc.2021.103278_bib0115","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \"quality of evidence\" and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103278_bib0120","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3109\/02841869609109921","article-title":"Radiosensitivity of mesothelioma cell lines","volume":"35","author":"Hakkinen","year":"1996","journal-title":"Acta Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103278_bib0125","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1148\/radiology.211.3.r99jn03657","article-title":"Malignant pleural mesothelioma: US-guided histologic core-needle biopsy","volume":"211","author":"Heilo","year":"1999","journal-title":"Radiology"},{"issue":"10","key":"10.1016\/j.critrevonc.2021.103278_bib0130","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/jclinpath-2013-201609","article-title":"Challenges and controversies in the diagnosis of malignant mesothelioma: part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA","volume":"66","author":"Henderson","year":"2013","journal-title":"J. Clin. Pathol."},{"issue":"11","key":"10.1016\/j.critrevonc.2021.103278_bib0135","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"issue":"7414","key":"10.1016\/j.critrevonc.2021.103278_bib0140","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2021.103278_bib0145","series-title":"SEER Cancer Statistics Review, 1975-2016","author":"Howlader","year":"2021"},{"issue":"13","key":"10.1016\/j.critrevonc.2021.103278_bib0150","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: american society of clinical oncology clinical practice guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2021.103278_bib0155","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2008.20.3943","article-title":"Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma","volume":"27","author":"Krug","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103278_bib0160","first-page":"162","article-title":"Malignant mesothelioma of the pleura: clinical aspects and symptomatic treatment","volume":"65","author":"Law","year":"1984","journal-title":"Eur. J. Respir. Dis."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103278_bib0165","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.lungcan.2009.06.014","article-title":"Prophylactic radiotherapy to intervention sites in mesothelioma: a systematic review and survey of UK practice","volume":"66","author":"Lee","year":"2009","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103278_bib0170","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1097\/JTO.0000000000000499","article-title":"Is radiotherapy useful for treating pain in mesothelioma?: a phase II trial","volume":"10","author":"MacLeod","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103278_bib0175","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.lungcan.2007.12.022","article-title":"Local recurrence of tumor at sites of intervention in malignant pleural mesothelioma","volume":"61","author":"Metintas","year":"2008","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103278_bib0180","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int. J. Surg."},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103278_bib0185","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1183\/09031936.00000811","article-title":"Predicting survival in malignant mesothelioma","volume":"38","author":"Musk","year":"2011","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103278_bib0190","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1510\/icvts.2011.267252","article-title":"Should all patients who have mesothelioma diagnosed by video-assisted thoracoscopic surgery have their intervention sites irradiated?","volume":"13","author":"Nagendran","year":"2011","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103278_bib0195","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.radonc.2007.05.022","article-title":"A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma","volume":"84","author":"O\u2019Rourke","year":"2007","journal-title":"Radiother. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2021.103278_bib0200","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.1989.7.8.1157","article-title":"Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients","volume":"7","author":"Ruffie","year":"1989","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103278_bib0205","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"Guidelines of the european respiratory society and the european society of thoracic surgeons for the management of malignant pleural mesothelioma","volume":"35","author":"Scherpereel","year":"2010","journal-title":"Eur. Respir. J."},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103278_bib0210","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1002\/1097-0142(19801215)46:12<2736::AID-CNCR2820461233>3.0.CO;2-L","article-title":"Latency of asbestos disease among insulation workers in the United States and Canada","volume":"46","author":"Selikoff","year":"1980","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2021.103278_bib0215","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103278_bib0220","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.radonc.2006.06.002","article-title":"The role of radiation therapy in malignant pleural mesothelioma: a systematic review","volume":"80","author":"Ung","year":"2006","journal-title":"Radiother. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103278_bib0225","first-page":"E254","article-title":"Guidelines for the diagnosis and treatment of malignant pleural mesothelioma","volume":"5","author":"van Zandwijk","year":"2013","journal-title":"J. Thorac. Dis."},{"issue":"14","key":"10.1016\/j.critrevonc.2021.103278_bib0230","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2021.103278_bib0235","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1016\/S1470-2045(16)30387-4","article-title":"Prophylactic radiotherapy to prevent procedure-tract metastases","volume":"17","author":"Zalcman","year":"2016","journal-title":"Lancet Oncol."},{"issue":"10026","key":"10.1016\/j.critrevonc.2021.103278_bib0240","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"29","key":"10.1016\/j.critrevonc.2021.103278_bib0245","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1200\/JCO.19.00927","article-title":"Trials of prophylactic irradiation of tracts: what is the appropriate end point?","volume":"37","author":"Zalcman","year":"2019","journal-title":"J. Clin. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821000664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821000664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:37:02Z","timestamp":1760902622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842821000664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":49,"alternative-id":["S1040842821000664"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103278","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma: A systematic review and meta-analysis of randomized trials","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103278","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103278"}}